Concluding, knowledge of FCGR2/3 genetic variation in autoinflammatory and autoimmune diseases may increase our knowledge on the pathophysiology of these complicated and multifactorial diseases, and may be related to effectiveness of IVIg therapy. This evidence concerns the gene FCGR2A and autoimmune disease.